TY - JOUR
T1 - Next-generation anti-VEGF agents for diabetic macular oedema
AU - Iglicki, Matias
AU - González, David Pérez
AU - Loewenstein, Anat
AU - Zur, Dinah
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
PY - 2022/2
Y1 - 2022/2
N2 - The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life.
AB - The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life.
UR - http://www.scopus.com/inward/record.url?scp=85112629771&partnerID=8YFLogxK
U2 - 10.1038/s41433-021-01722-8
DO - 10.1038/s41433-021-01722-8
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 34373607
AN - SCOPUS:85112629771
SN - 0950-222X
VL - 36
SP - 273
EP - 277
JO - Eye
JF - Eye
IS - 2
ER -